Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Hans‐Peter Brunner‐La Rocca et al.|New England Journal of Medicine|2021Cited by 4.6k
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesStuart Pocock, Robert N. Doughty, Cono Ariti et al.|European Heart Journal|2012Cited by 1.3k
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R. Kalra, Claes Christian Strom, John G.F. Cleland et al.|The Lancet|2022Cited by 367
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialStefan D. Anker, Milton Packer, Javed Butler et al.|European Journal of Heart Failure|2020Cited by 135
Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart FailureLeong L. Ng, Christian Mueller, Iain Squire et al.|Journal of the American College of Cardiology|2017Cited by 90